Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) (TRILOGY 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03398005
Recruitment Status : Active, not recruiting
First Posted : January 12, 2018
Last Update Posted : July 15, 2019
Sponsor:
Information provided by (Responsible Party):
Acasti Pharma Inc.

Tracking Information
First Submitted Date  ICMJE November 21, 2017
First Posted Date  ICMJE January 12, 2018
Last Update Posted Date July 15, 2019
Actual Study Start Date  ICMJE January 23, 2018
Estimated Primary Completion Date July 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 10, 2018)
Percent change in fasting TG levels from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L). [ Time Frame: Week 12 ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03398005 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 10, 2018)
  • Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in non-HDL-C. [ Time Frame: Week 12 ]
  • Percent change from baseline (Week -1 and 0) to Week 12 (average of Week 11 and 12) in VLDL-C (β-quantification). [ Time Frame: Week 12 ]
  • Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in HDL-C. [ Time Frame: Week 12 ]
  • Percent change from baseline (average of Week -1 and 0) to Week 12 (average of Week 11 and 12) in LDL-C (β-quantification). [ Time Frame: Week 12 ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: January 10, 2018)
  • Percent change from baseline (average of Week -2, -1, and 0) to all measured visits other than Week 12 (Week 4, Week 18 and Week 26) in TG (persistence of the effect of CaPre on TG). [ Time Frame: Week 4; Week 18; Week 24 ]
  • Proportion of subjects with a fasting TG level below 500 mg/dL (<5.7 mmol/L) at Week 12 and at Week 26. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and Week 12) and Week 26 in TC. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (average of Week -1 and 0) to Week 12 (average of Week 11 and 12) and to Week 26 in RLP-C. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (average of Week -1 and 0) to Week 26 in LDL-C (β-quantification) and VLDL-C (β-quantification). [ Time Frame: Week 26 ]
  • Percent change from baseline (average of Week -2, -1, and 0) to Week 26 in non-HDL-C and HDL-C. [ Time Frame: Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in apo B, apo A1, apo B/apo A1 ratio, apo CIII and apo A5. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in lipoprotein particles concentration and size (LDL, non-HDL, HDL, IDL and VLDL). [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in oxidized LDL. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in fasting serum glucose, insulin and HbA1c. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in HOMA-IR and HOMA-β. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in hs-CRP and Lp-PLA2. [ Time Frame: Week 12; Week 26 ]
  • Change from baseline (Week 0) to Week 4, Week 12, Week 18 and to Week 26 in Total plasma EPA concentration and Total plasma DHA concentration. [ Time Frame: Week 4; Week 12; Week 18; Week 26 ]
  • Percent change from baseline (Week 0) to Week 4, Week 12, Week 18 and to Week 26 in Total plasma EPA concentration and Total plasma DHA concentration. [ Time Frame: Week 4; Week 12; Week 18; Week 26 ]
  • Change from baseline (Week 0) to Week 12 and to Week 26 in OM3 Index. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in OM3 Index. [ Time Frame: Week 12; Week 26 ]
  • Change from baseline (Week 0) to Week 12 and to Week 26 in AA. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in AA. [ Time Frame: Week 12; Week 26 ]
  • Change from baseline (Week 0) to Week 12 and to Week 26 in omega-6/omega-3 ratio. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in omega-6/omega-3 ratio. [ Time Frame: Week 12; Week 26 ]
  • Change from baseline (Week 0) to Week 12 and to Week 26 in EPA/AA ratio. [ Time Frame: Week 12; Week 26 ]
  • Percent change from baseline (Week 0) to Week 12 and to Week 26 in EPA/AA ratio. [ Time Frame: Week 12; Week 26 ]
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)
Official Title  ICMJE A Phase 3, Multi-center, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia.
Brief Summary

The primary objective of this study is to determine the efficacy of CaPre 4 g daily, compared to placebo, in lowering fasting triglyceride (TG) levels in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L) after 12 weeks of treatment.

Approximately 615 subjects will be screened to obtain 245 randomized subjects following a 2.5:1 treatment allocation ratio (CaPre: placebo).

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Hypertriglyceridemia
Intervention  ICMJE
  • Drug: CaPre
    4 x 1 g capsules administered orally once a day for 26 weeks
  • Drug: Placebo
    4 x 1 g capsules administered orally once a day for 26 weeks
Study Arms  ICMJE
  • Experimental: CaPre
    Intervention: Drug: CaPre
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Estimated Enrollment  ICMJE
 (submitted: January 10, 2018)
245
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE November 2019
Estimated Primary Completion Date July 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Subjects ≥18 years of age.
  2. Isolated hypertriglyceridemia, with triglycerides ≥500 mg/dL and <1500 mg/dL (≥5.7 mmol/L and <17.0 mmol/L) OR Mixed hyperlipidemia, with serum triglycerides ≥500 and <1500 mg/dL treated with a statin, CAI or PCSK9I inhibitor, alone or in combination, that has been stable for 6 weeks prior to randomization. If the subject is not being treated and not contraindicated, a statin and/or CAI treatment may be initiated at the discretion of the Investigator at time of screening.
  3. Willingness to maintain current physical activity level and follow the NCEP-TLC diet throughout the study.
  4. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion Criteria:

  1. Allergy or intolerance to OM3 fatty acids, OM3-acid ethyl esters, OM3 phospholipids, fish, shell fish, or any component of the study medication.
  2. Known lipoprotein lipase impairment or deficiency, or apo CII deficiency.
  3. Subjects with lysosomal acid lipase deficiency.
  4. Body mass index greater than 45 kg/m2.
  5. Subjects who are pregnant, lactating, and subjects of childbearing potential who are either planning to become pregnant or who are not using acceptable birth control methods during study participation. Subjects of childbearing potential are subjects who have experienced menarche and do not otherwise meet the criteria for subjects not of childbearing potential, defined as:

    • Subjects who have had surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation); or
    • Subjects who are postmenopausal, i.e., who have had a cessation of menses for at least 12 months without an alternative medical cause. A follicle stimulating hormone (FSH) test ≥40 mIU/mL may be used to confirm the post-menopausal state in women not using hormonal contraception or hormonal replacement therapy.

    Subjects of childbearing potential must test negative for pregnancy at the time of enrollment and agree to use an acceptable contraceptive method or remain abstinent during the study or for at least 8 weeks following the last dose of study medication, whichever is longer.

  6. Subjects taking tamoxifen, estrogens, or progestins, or other medications or nutritional supplements with mechanisms modifying estrogen or progestogen pathways, who have had dosage changes within 4 weeks prior to Visit 1.
  7. Use of oral or injected corticosteroids or anabolic steroids within 6 weeks prior to randomization.
  8. History of pancreatitis within the last 6 months prior to Visit 1.
  9. History of symptomatic gallstone disease within the last 5 years, unless treated with cholecystectomy.
  10. Diabetics requiring changes in medical therapy (other than short acting insulin dosage adjustments) within 6 weeks prior to Visit 1 or who have HbA1c greater than 9.5% at Visit 1.
  11. Clinical or biochemical evidence of hyperthyroidism not stable with medication for at least 6 weeks prior to Visit 1.
  12. Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH) level more than 1.5 × upper limit of normal (ULN).
  13. Thyroid hormone replacement therapy that has not been stable for more than 6 weeks prior to Visit 1.
  14. History of cancer (other than basal cell carcinoma) within 2 years prior to Visit 1.
  15. Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient ischemic attack, exacerbation of congestive heart failure requiring hospitalization or a change in treatment), life threatening arrhythmia, or revascularization procedure within 6 months prior to Visit 1.
  16. Use of other prohibited drugs: weight loss prescription medications; human immunodeficiency virus (HIV) protease inhibitors; cyclophosphamide; isotretinoin; routine or anticipated use of systemic corticosteroids (local, topical, inhalation, or nasal corticosteroids are permitted); or anabolic steroids.
  17. Use of any lipid-altering drug therapy, other than statins, CAI (such as ezetimibe) or PCSK9I inhibitors, alone or in combination, including niacin at a dose greater than 200 mg/day, fibrates, bile acid sequestrants, OM3 drugs (e.g., Lovaza or its generics,Vascepa, Epanova, Omtryg), OM3 supplements (e.g., fish oil, krill oil products), or any other herbal products or dietary supplements with potential lipid-altering effects. These products must be discontinued at least 6 weeks prior to randomization.
  18. Resection of an aortic aneurysm or endovascular aortic repair within 6 months prior to Visit 1.
  19. Recent history (within 6 months prior to Visit 1) or current significant nephrotic syndrome or ≥3 gram proteinuria daily, pulmonary, gastrointestinal, or immunologic disease.
  20. Poorly controlled hypertension (systolic blood pressure ≥170 mmHg and/or diastolic blood pressure ≥100 mmHg). Subjects with hypertension adequately controlled with medication are eligible provided that their antihypertensive therapy has been stable for at least 4 weeks prior to Visit 1.
  21. Recent history (past 12 months) of drug abuse or alcohol abuse, or alcohol use greater than 2 units per day (a unit of alcohol is defined as a 12-ounce (350 mL) beer, 5 ounce (150 mL) wine, or 1.5-ounce (45 mL) of 80-proof alcohol for drinks).
  22. Hepatobiliary disease or serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >5× ULN; if ALT/AST is >3× ULN, the levels must have been stable for 3 months prior to Visit 1.
  23. Severe renal disease as defined by less than 30 mL/min serum creatinine clearance calculated using the Cockcroft-Gault formula.
  24. Significant coagulopathy as defined by a known hereditary deficiency of coagulation factors or platelet function or an unexplained elevation of the prothrombin time (PT) international normalized ratio (INR) of ≥1.5. Subjects using warfarin [Coumadin®] or heparin are allowed. Subjects receiving other anticoagulants dabigatran, rivaroxaban, or apixaban are allowed. Subjects receiving acetylsalicylic acid (ASA) alone or in combination with other anti platelet agents (e.g., clopidogrel, prasugrel, ticagrelor) are also allowed.
  25. Unexplained creatine kinase concentration 3 × ULN.
  26. Creatine kinase elevation owing to known hereditary or acquired muscle disease.
  27. Exposure to any investigational product, within 4 weeks prior to Visit 1.
  28. Presence of any other condition the Investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.
  29. Any life-threatening disease expected to result in death within 2 years, require frequent hospitalizations, extensive surgery or changes in medications or diet.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03398005
Other Study ID Numbers  ICMJE ACA-CAP-001
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Acasti Pharma Inc.
Study Sponsor  ICMJE Acasti Pharma Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Dariush Mozaffarian, MD, DrPH Tufts Friedman School of Nutrition Science and Policy
PRS Account Acasti Pharma Inc.
Verification Date July 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP